| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Personalis, Inc. Common Stock$13.2
+0.44 (+3.48%)
F 16Pipeline Score Tools & Services · Commercial
Market Cap
629.88 M
EPS
-0.91
P/E Ratio
-6.62 $
Value Trade
31.35 M
SEC Financials
Q1 2026Dilution Risk
Revenue
15.47 M
R&D Expenses
14.54 M
Operating CF
-22.48 M
Total Assets
325.39 M
Total Liabilities
70.63 M
Equity
254.76 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
233.22 M
Monthly Burn
7.49 M
Runway
28.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
4.85 M
52 Week Range
3.09 - 11.50
% held by Insiders
32.61 %
% held by Institutions
61.95 %
Enterprise Value
430.74 M
Total Shares
104.67 M
Short %
15.43 %
Float Shares
59.45 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 13%
Micro Cap (rank 804 of 923)
Percentile RankPersonalis, Inc. Common Stock has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pembrolizumab | high-risk stage II-III dMMR/MSI-H colorectal cancer | — | 2026-04-21 | 100% sensitivity for disease at baseline; 100% of 'super molecular responders' achieved pCR; 100% of 'poor molecular responders' did not achieve pCR; 100% negative predictive value (NPV) post-surgery; 100% specificity for disease relapse; 39% of all positive MRD detections occurred in the ultrasensitive range below 100 PPM; 14.6% below 10 PPM; >99.9% specificity for resistance mutations; 38% of MRD-positive patients had resistance mutations; 100% progression-free at three years for patients with durable molecular complete response Read More | Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 Read More | |
pembrolizumab | high-risk stage II-III dMMR/MSI-H colorectal cancer | — | 2026-04-21 | 100% sensitivity for disease at baseline; 100% of 'super molecular responders' achieved pCR; 100% of 'poor molecular responders' did not achieve pCR; 100% negative predictive value (NPV) post-surgery; 100% specificity for disease relapse; 39% of all positive MRD detections occurred in the ultrasensitive range below 100 PPM; 14.6% below 10 PPM; >99.9% specificity for resistance mutations; 38% of MRD-positive patients had resistance mutations; 100% progression-free at three years for patients with durable molecular complete response Read More | Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 Read More | |
pembrolizumab | high-risk stage II-III dMMR/MSI-H colorectal cancer | — | 2026-04-21 | 100% sensitivity for disease at baseline; 100% of 'super molecular responders' achieved pCR; 100% of 'poor molecular responders' did not achieve pCR; 100% negative predictive value (NPV) post-surgery; 100% specificity for disease relapse; 39% of all positive MRD detections occurred in the ultrasensitive range below 100 PPM; 14.6% below 10 PPM; >99.9% specificity for resistance mutations; 38% of MRD-positive patients had resistance mutations; 100% progression-free at three years for patients with durable molecular complete response Read More | Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PSNL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PSNL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PSNL
Jul 20, 2026▼ -13.3%on this news
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Tempus AI, Inc. has announced its acquisition of Personalis, Inc. to enhance its precision oncology platform. This strategic move aims to improve capabilities in minimal residual disease (MRD), allowing for better patient support throughout diagnosis, treatment selection, and monitoring. The integration is expected to significantly advance Tempus' AI-driven healthcare solutions.
Read more →-PSNL
Jul 14, 2026Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
Personalis, Inc. has received UKCA marking for its NeXT Personal Dx test, allowing clinical use of its Minimal Residual Disease detection technology in Great Britain. This regulatory approval is a significant step for the company, enhancing its support for biopharma and increasing access to advanced genomic testing in the region.
Read more →-PSNL
Jun 9, 2026Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis has announced the launch of CE-IVD marked specimen collection kits aimed at supporting global biopharma initiatives. These kits are designed to enhance the efficiency of specimen collection while ensuring compliance with European regulations. The move is expected to bolster Personalis's position in the biopharma market.
Read more →-PSNL
Jun 2, 2026Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis presented findings on early colorectal cancer recurrence detection and the performance of ultrasensitive minimal residual disease (MRD) detection across various tumor types at ASCO 2026. The details of the findings were not disclosed in the article.
Read more →-PSNL
May 26, 2026▲ +5.5%on this news· ran to +35% by day 3
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Personalis will showcase the capabilities of its NeXT Personal® ultra-sensitive ctDNA data at the ASCO 2026 Annual Meeting. The presentation will include insights from the TRACERx Consortium, highlighting the advancements in cancer detection and monitoring. This event aims to emphasize the importance of ctDNA in personalized medicine.
Read more →-PSNL
May 20, 2026▲ +12.9%on this news· ran to +27% by day 3shared move
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis has successfully secured a fourth Medicare coverage decision for its NeXT Personal® test, which now includes coverage for pre-surgical treatment monitoring in breast cancer patients. This expansion is expected to enhance patient care by providing more comprehensive monitoring options. The decision reflects growing recognition of the test's value in personalized cancer treatment.
Read more →-PSNL
May 14, 2026▲ +5%on this news
Personalis to Participate in Upcoming Investor Events
Personalis is set to participate in upcoming investor events, showcasing its commitment to engaging with stakeholders. The events aim to provide insights into the company's progress and future plans. Further details about the events and their significance were not disclosed in the article.
Read more →-PSNL
May 13, 2026▲ +5.8%on this newsshared move
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis has secured Medicare coverage for its NeXT Personal® test, which is designed for immunotherapy monitoring in patients with late-stage solid tumors. This development is expected to improve access to personalized cancer treatment options. The coverage represents a significant advancement in the integration of genomic testing into clinical practice.
Read more →-PSNL
May 7, 2026Personalis Reports First Quarter Results and Recent Highlights
Personalis has reported its first quarter results, but the article provides minimal details on financial performance or significant highlights. The content is primarily focused on privacy aspects, leaving out critical business insights. Stakeholders may find the lack of concrete information concerning.
Read more →-PSNL
Apr 23, 2026▼ -6.5%on this news
Personalis to Announce First Quarter 2026 Financial Results
Personalis, Inc. will announce its first quarter 2026 financial results on May 7, 2026. The company will host a conference call and webcast at 2:00 p.m. PT to discuss these results and recent highlights. Interested parties can access the call via phone or through the company's website.
Read more →-PSNL
Apr 21, 2026Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
Personalis, Inc. presented promising clinical data at the AACR Annual Meeting, showcasing the effectiveness of their NeXT Personal ultrasensitive ctDNA assay in monitoring treatment responses and tracking therapy resistance. Key findings included high sensitivity in detecting disease and the introduction of a new feature for real-time tracking of mutations. These advancements could significantly enhance cancer management strategies.
Read more →-PSNL
Apr 13, 2026Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis, Inc. will present new data on its NeXT Personal ctDNA assay at the AACR Annual Meeting 2026. The highlight includes the Real-Time Variant Tracker, which tracks therapy resistance mutations. Presentations will cover various aspects of colorectal cancer management and the assay's clinical impact, showcasing Personalis' commitment to innovation in cancer care.
Read more →-PSNL
Feb 27, 2026Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis, Inc. reported significant growth in 2025, highlighted by a 400% increase in clinical volume and new Medicare coverage for breast and lung cancer. The company anticipates a robust financial outlook for 2026, projecting a five-fold increase in clinical revenue. CEO Chris Hall emphasized the importance of their 'Win-in-MRD' strategy and a strong cash position to support expansion efforts.
Read more →-PSNL
Feb 18, 2026▲ +5%on this news
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
Personalis, Inc. will participate in the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, in Boston. The company's management team will present its advancements in genomics for precision oncology. Personalis aims to enhance cancer management through personalized testing and advanced insights into tumor profiling.
Read more →-PSNL
Feb 2, 2026Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Personalis, Inc. has published a study demonstrating the effectiveness of its NeXT Personal test in monitoring immunotherapy responses in advanced cancer patients. The study, conducted by UC San Diego researchers, highlights the assay's ultrasensitive detection of circulating tumor DNA (ctDNA), which can lead to earlier clinical interventions. This research builds on previous findings and emphasizes the need for improved monitoring tools in cancer treatment.
Read more →-PSNL
Jan 29, 2026Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. The event will take place at the Cliff Lodge in Snowbird, Utah. The company focuses on advanced genomics for precision oncology, providing personalized testing and insights for cancer management.
Read more →-PSNL
Jan 8, 2026▼ -10.4%on this news
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights ○ Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms in
Personalis, Inc. reported preliminary financial results for Q4 and full year 2025, noting a substantial increase in clinical test volumes and a strong cash position. The company's revenue for Q4 is projected between $17 and $18 million, contributing to a total expected annual revenue of $69 to $70 million. Notably, Personalis secured Medicare coverage for breast cancer surveillance, a key milestone that enhances its market position. However, revenue for 2025 is anticipated to fall short of 2024 figures, presenting concerns about future growth.
Read more →-PSNL
Nov 4, 2025Personalis Reports Third Quarter 2025 Financial Results Company Advances Win-in-MRD Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal Platform FREMONT, Calif. –
Personalis, Inc. reported its third quarter 2025 financial results, highlighting significant operational momentum with a 364% year-over-year increase in clinical tests delivered. The company advanced its Win-in-MRD strategy and showcased compelling clinical data, including results from AstraZeneca's NeoADAURA trial. Despite these positive developments, the company experienced a 44% decline in revenue compared to the previous year, with a noted decrease in gross margins. Looking ahead, Personalis adjusted its revenue guidance for the full year 2025, signaling continuing challenges amid its advancements.
Read more →-PSNL
Aug 5, 2025Personalis Reports Second Quarter 2025 Financial Results Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume
Personalis, Inc. reported a strong financial performance for Q2 2025, showcasing a 59% sequential growth in clinical test volume driven by its Win-in-MRD strategy. CEO Chris Hall highlighted the adoption of their MRD platform aided by recent clinical data presented at ASCO. Despite these positive results, the company acknowledged facing temporary challenges in the biopharma sector. Future revenue guidance remains contingent upon securing Medicare coverage for certain indications as they progress through 2025.
Read more →-PSNL
May 6, 2025▼ -6.1%on this news· ran to +18% by day 3
Personalis Reports First Quarter 2025 Financial Results Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year
Personalis, Inc. has reported a strong start to Q1 2025, with clinical test volume rising by 52% and pharma tests and services revenue increasing by 39% year-over-year. The CEO expressed confidence in the effectiveness of their Win-in-MRD strategy and the growth of their NeXT Personal platform. However, the company also faces challenges, including a net loss of $15.7 million and uncertainties surrounding reimbursement for their tests.
Read more →-PSNL
Feb 27, 2025▼ -5.4%on this news
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow brea
Personalis, Inc. reported a 15% increase in full year revenue for 2024, totaling $84.6 million. The company ended the year with a cash balance of $185 million, which is expected to support its path to cash flow break-even. Additional highlights include strong growth in molecular testing and promising partnerships with Tempus and Moderna. The financial results reflect significant advancements in the company's business strategy for precision oncology.
Read more →-PSNL
Jan 7, 2025▼ -6.7%on this news
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash flo
Personalis, Inc. has reported preliminary revenue for the fourth quarter and full year ending December 31, 2024, with full-year revenue reaching approximately $84.6 million, marking a 15% increase from the previous year. The company also announced a cash balance of roughly $185 million, which is expected to help them reach cash flow break-even. CEO Chris Hall highlighted achievements in establishing a long-term collaboration with Moderna and securing a $50 million investment from Merck, confirming confidence in their technology platform.
Read more →-PSNL
Nov 6, 2024Personalis Reports Third Quarter 2024 Financial Results 41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Mill
Personalis, Inc. reported its third quarter 2024 financial results, showcasing a 41% year-over-year revenue increase, largely driven by a 96% growth in biopharma revenues. The company raised its 2024 revenue guidance, reflecting strong recent performance and customer confidence in its technologies. A cash reserve of $143.7 million sets a solid foundation for operations through the first half of 2027. Additionally, the presentation of significant clinical data at the ESMO Congress underscores the potential value of its NeXT Personal test in oncology.
Read more →-PSNL
Aug 16, 2024▲ +18.1%on this news
Personalis and Tempus Announce Expanded Collaboration Tempus invests $36 million by exercising warrants and purchasing additional shares
Personalis, Inc. and Tempus AI, Inc. have expanded their collaboration, with Tempus investing $36 million by exercising warrants and purchasing additional shares. This partnership aims to bring ultra-sensitive minimal residual disease (MRD) testing to market, particularly for breast and lung cancers. The investment reflects strong demand for Personalis's proprietary testing solutions. Challenges include the need to manage increased patient sample processing and reliance on Tempus’s marketing efforts for the initiative's success.
Read more →-PSNL
Aug 7, 2024▼ -10%on this news· ran to +35% by day 3
Personalis Reports Second Quarter 2024 Financial Results Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance FREMONT, Calif. –
Personalis, Inc. reported a strong financial performance for Q2 2024, with a 35% increase in total revenue compared to the previous year, primarily driven by a 117% rise in its biopharma segment. The company also showcased promising clinical results for its NeXT Personal test at the ASCO meeting, highlighting its capability in early cancer detection and monitoring during immunotherapy. However, despite these advancements, Personalis still incurred a net loss of $12.8 million and experienced a drop in revenue from its population sequencing efforts. The company has raised its revenue guidance for the full year 2024, reflecting increased confidence in its growth trajectory.
Read more →-PSNL
May 8, 2024Personalis Reports First Quarter 2024 Financial Results Raises full year revenue guidance due to greater pharma testing demand FREMONT, Calif. –
Personalis, Inc. reported strong financial results for Q1 2024, achieving revenues of $19.5 million, which exceeded their guidance. The company raised its full-year revenue forecast due to an increase in demand for pharma testing services, which saw a 55% growth year-over-year. Highlights from the quarter include the publication of their NeXT Personal MRD test's analytical validation, and five abstracts accepted for the ASCO medical conference. Despite a net loss of $13.0 million, improvements were seen compared to the prior year, although some revenue segments, such as enterprise customers and population sequencing, experienced declines.
Read more →-PSNL
Feb 28, 2024Personalis Reports Fourth Quarter and Full Year 2023 Financial Results FREMONT, Calif. –
Personalis, Inc. announced its financial results for Q4 and the full year 2023, showcasing an 18% revenue increase in the fourth quarter. The company secured Medicare coverage for its NeXT Dx test and formed strategic partnerships to bolster its tumor-informed testing capabilities. However, it reported a net loss of $26.6 million in the fourth quarter. Looking ahead, Personalis projects total revenue of $73.0 to $75.0 million for 2024, amidst a focus on cost management and clinical evidence generation.
Read more →-PSNL
Jan 5, 2024▲ +7%on this news
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance FREMONT, CA
Personalis, Inc. reported strong preliminary revenue figures for both the fourth quarter and full year ended December 31, 2023. The company experienced an 18% increase in revenue for the fourth quarter, totaling $19.7 million, while full-year revenue reached $73.5 million, up 13% from 2022. Despite a decrease in revenue from Natera, the company reported a solid cash balance of $114 million, anticipated to sustain operations through early 2026. CEO Chris Hall emphasized the importance of new product launches and cost-cutting measures that have enhanced the company’s financial health.
Read more →-PSNL
Nov 7, 2023▼ -9.2%on this news
Personalis Reports Third Quarter 2023 Financial Results Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting Next Personal's market leading sensitivity for cance
Personalis, Inc. reported a significant revenue growth of 23% in the third quarter of 2023, totaling $18.2 million compared to the previous year. The company highlighted its leading cancer detection capabilities through clinical data supporting the NeXT Personal test. Despite the revenue growth, Personalis faced a net loss of $29.1 million, which included a notable impairment charge. The company also raised its full-year revenue guidance, projecting total revenues between $73 and $74 million for 2023.
Read more →-PSNL
Aug 8, 2023Personalis Reports Second Quarter 2023 Financial Results FREMONT, Calif. –
Personalis, Inc. reported its second quarter financial results with an 8% decrease in total revenue, amounting to $16.7 million, and a net loss of $24.0 million. The company has established a new collaboration aimed at predicting immunotherapy responses and plans to launch a highly sensitive minimal residual disease (MRD) test later this year. Despite financial setbacks, Personalis anticipates revenue growth in the coming quarters, having tightened its guidance for total revenue for the year. Additionally, the firm is currently engaged in legal actions to protect its intellectual property.
Read more →-PSNL
May 3, 2023▲ +10%on this news
Personalis Reports First Quarter 2023 Financial Results FREMONT, Calif. –
Personalis, Inc. reported its financial results for Q1 2023, highlighting a 24% revenue increase to $18.9 million. The company announced collaborations with notable institutions to advance cancer detection technologies using its NeXT Personal assay. Despite the positive revenue growth, Personalis faced a net loss of $28.7 million and expects further losses throughout the year. The outlook includes projected total revenues of $68 million to $72 million for 2023, amid ongoing reliance on customer orders for financial stability.
Read more →-PSNL
Feb 23, 2023Personalis Reports Fourth Quarter and Full Year 2022 Financial Results FREMONT, Calif. –
Personalis, Inc. has reported its financial results for Q4 and the full year of 2022, revealing total revenues of $16.7 million for the quarter and $65 million for the year. The company highlighted its strategic partnerships, notably with Moderna for genomic testing in personalized cancer vaccines, and its initiative to improve cancer treatment monitoring through new research collaborations. Despite the positive business developments, Personalis recorded a significant net loss of $31.1 million in Q4 2022, raising concerns about future revenue impacts due to customer ordering uncertainties.
Read more →-PSNL
Jan 4, 2023▲ +8.5%on this news
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue FREMONT, Calif. –
Personalis, Inc. reported its preliminary revenue for Q4 and the full year of 2022, highlighting approximately $16.7 million for Q4 and about $65.0 million for the entire year. This revenue exceeded previous guidance, driven by a notable 42% growth in biopharma revenue. However, revenue from the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) saw a significant decline, dropping 82% compared to 2021. The company noted unfulfilled orders in the VA MVP, although it expects to recognize some of these orders as revenue in the first half of 2023.
Read more →-PSNL
Nov 2, 2022Personalis Reports Third Quarter 2022 Financial Results MENLO PARK, Calif. –
Personalis Reports Third Quarter 2022 Financial Results MENLO PARK, Calif. November 2, 2022 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022. Third Quarter and
Read more →-PSNL
Aug 3, 2022▲ +10.1%on this news
Personalis Reports Second Quarter 2022 Financial Results
Personalis Reports Second Quarter 2022 Financial Results MENLO PARK, Calif. - August 3, 2022 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022. Second Quarter and
Read more →-PSNL
May 4, 2022Personalis Reports First Quarter 2022 Financial Results
Personalis Reports First Quarter 2022 Financial Results MENLO PARK, Calif. - May 4, 2022 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. First Quarter and Recen
Read more →-PSNL
Mar 24, 2022Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors Personalis oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing reven
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors Personalis oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing revenue from pharmaceutical companies MENLO PARK, Calif. (BUSI
Read more →-PSNL
Feb 24, 2022▲ +9.6%on this news
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif. - February 24, 2022 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended Dece
Read more →-PSNL
Jan 6, 2022Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue MENLO PARK, Calif. - January 6, 2022 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarte
Read more →-PSNL
Nov 4, 2021▲ +6%on this news
Personalis Reports Third Quarter 2021 Financial Results
Personalis Reports Third Quarter 2021 Financial Results MENLO PARK, Calif. - November 4, 2021 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the third quarter ended September 30, 2021.
Read more →-PSNL
Aug 4, 2021Personalis Reports Second Quarter 2021 Financial Results
Personalis Reports Second Quarter 2021 Financial Results MENLO PARK, Calif. - August 4, 2021 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021. Secon
Read more →-PSNL
May 5, 2021Personalis Reports First Quarter 2021 Financial Results
Personalis Reports First Quarter 2021 Financial Results MENLO PARK, Calif. - May 5, 2021 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended March 31, 2021. First Qua
Read more →-PSNL
Feb 25, 2021Personalis Reports Fourth Quarter and Full Year 2020 Financial Results
Personalis Reports Fourth Quarter and Full Year 2020 Financial Results MENLO PARK, Calif. - February 25, 2021 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full y
Read more →-PSNL
Jan 11, 2021Personalis Reports Preliminary Fourth Quarter 2020 Revenue
Personalis Reports Preliminary Fourth Quarter 2020 Revenue MENLO PARK, Calif. - January 11, 2021 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full ye
Read more →-PSNL
Nov 5, 2020Personalis Reports Third Quarter 2020 Financial Results
Personalis Reports Third Quarter 2020 Financial Results MENLO PARK, Calif. - November 5, 2020 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020.
Read more →-PSNL
Aug 6, 2020Personalis Reports Second Quarter 2020 Financial Results
Personalis Reports Second Quarter 2020 Financial Results MENLO PARK, Calif. - August 6, 2020 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020. Second Quarter Highlights "I'm
Read more →-PSNL
May 7, 2020Personalis Reports First Quarter 2020 Financial Results
Personalis Reports First Quarter 2020 Financial Results MENLO PARK, Calif. - May 7, 2020 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the first quarter ended March 31, 2020. First Quarter Highlights "I'm prou
Read more →-PSNL
Mar 25, 2020Personalis Reports Fourth Quarter and Full Year 2019 Financial Results
Personalis Reports Fourth Quarter and Full Year 2019 Financial Results MENLO PARK, Calif. - March 25, 2020 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019.
Read more →-PSNL
Nov 13, 2019Personalis Reports Third Quarter 2019 Financial Results
Personalis Reports Third Quarter 2019 Financial Results MENLO PARK, Calif. - November 13, 2019 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highli
Read more →-PSNL
Aug 13, 2019Personalis Reports Second Quarter 2019 Financial Results
Personalis Reports Second Quarter 2019 Financial Results MENLO PARK, Calif. - August 13, 2019 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2019. Second Quarter 2019 Highlights
Read more →Competitive Position
How PSNL ranks across every disease it competes inCompetitive Position is a premium feature
See how PSNL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial